Jeito Capital — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Pulmocidepulmocide.cominDec 2022 · $52M
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin
Co-investorsAdjuvant CapitalF-Prime CapitalLongwood FundSR One Capital ManagementSV Health InvestorsVivo Capital+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.